Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end – – Ongoing Merck collaboration to discover and develop …